Immunome, Inc. (NASDAQ: IMNM) is a Healthcare company (Biotechnology) with a market capitalization of $2.0B. The Maz Rating grades it against the other companies in its sector.
Immunome, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.18, Immunome, Inc. trades at 4.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -51.3%, return on invested capital of -64.6% and a free cash flow yield of -11.8%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 11.66. Over the past 52 weeks the share price ranged from $16.41 to $30.06, with a beta of 2.13.
Immunome, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 13 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Immunome, Inc. (IMNM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 18.4% / 30% · Interest income / Revenue 457900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 18.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 457900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 18.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 457900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.51% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.4% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 457900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 91.3% / 33.33% · (Cash+Recv) / Total Assets 91.3% / 33.33% · Interest income / Revenue 457900000.0% / 5% | Fail |
No. As of September 2026, Immunome, Inc. (IMNM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Immunome, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 457900000.0% of each dividend: Immunome, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.